抗EGFR再挑战在转移性结直肠癌三线治疗中的应用研究进展
Research Progress on Anti-EGFR Rechallenge for the Third-Line Therapy of Metastatic Colorectal Cancer
钟露慧 1熊英 1崔晋 1顾新月 1刘莉1
作者信息
- 1. 华中科技大学同济医学院附属协和医院肿瘤中心,湖北武汉 430023
- 折叠
摘要
表皮生长因子受体(epidermal growth factor receptor,EGFR)单克隆抗体是治疗转移性结直肠癌患者的有效一线药物.然而,抗EGFR治疗后获得性耐药的出现限制了 EGFR抑制剂在转移性结直肠癌持续治疗中的应用.基于分子生物学的研究,抗EGFR再挑战策略在RAS/BRAF野生型转移性结直肠癌患者二线治疗后的临床管理中具有潜在活性.全文综述了抗EGFR再挑战策略在转移性结直肠癌三线治疗中的疗效及其相关毒性,并探讨了疗效预测因素的研究进展,为临床实践和科学研究提供新的视角.
Abstract
The epidermal growth factor receptor(EGFR)monoclonal antibody is an effective first-line drug for metastatic colorectal cancer patients.However,the emergence of acquired resistance after anti-EGFR therapy limits the use of EGFR inhibitors in the sustained treatment of metastatic colorectal cancer.Based on molecular biology research,the anti-EGFR rechallenge strategy has potential activity in clinical management of RAS/BRAF wild-type metastatic colorectal cancer pa-tients after second-line treatment.This paper reviews the efficacy and related toxicity of the anti-EGFR rechallenge strategy in the third-line treatment of metastatic colorectal cancer,as well as the prediction factors for efficay,to provid a new perspective for clinical practice and scientific re-search.
关键词
结直肠肿瘤/肿瘤转移/表皮生长因子受体/再挑战/RAS野生型Key words
colorectal neoplasmas/tumor metastasis/epidermal growth factor receptor/rechallenge/RAS wild-type引用本文复制引用
出版年
2024
NETL
NSTL
万方数据